FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
+42.11%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$2.37B
AUM Growth
+$2.37B
(+27%)
Cap. Flow
+$123M
Cap. Flow
% of AUM
5.2%
Top 10 Holdings %
Top 10 Hldgs %
58.56%
Holding
56
New
7
Increased
13
Reduced
6
Closed
6
Top Buys
| 1 |
CG Oncology
CGON
|
$33.8M |
| 2 |
Oric Pharmaceuticals
ORIC
|
$27.5M |
| 3 |
PepGen
PEPG
|
$22.1M |
| 4 |
BridgeBio Pharma
BBIO
|
$21.3M |
| 5 |
Soleno Therapeutics
SLNO
|
$17.6M |
Top Sells
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$16.1M |
| 2 |
Dyne Therapeutics
DYN
|
$15.8M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
$14.1M |
| 4 |
89bio
ETNB
|
$11.6M |
| 5 |
Apogee Therapeutics
APGE
|
$11.2M |
Sector Composition
| 1 | Healthcare | 99.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Structure Therapeutics
GPCR
$1.11B
| $27M | 1.14% | 629,194 +312,004 | +98% | +$13.4M |
|
27
Trevi Therapeutics
TRVI
$883M
| $25.5M | 1.07% | 7,381,090 | – | – |
|
|
SLN
28
Silence Therapeutics
SLN
$227M
| $24.8M | 1.05% | 1,148,591 +267,418 | +30% | +$5.78M |
|
|
DCPH
29
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $22.9M | 0.97% | 1,455,837 +434,037 | +42% | +$6.83M |
|
|
30
PepGen
PEPG
$38M
| $22.1M | 0.93% | +1,502,788 | New | +$22.1M |
|
31
AnaptysBio
ANAB
$569M
| $20.3M | 0.85% | 899,700 | – | – |
|
32
Savara
SVRA
$567M
| $19.9M | 0.84% | 4,000,000 | – | – |
|
|
CERE
33
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $16.6M | 0.7% | 393,000 | – | – |
|
34
Agios Pharmaceuticals
AGIO
$2.19B
| $15.3M | 0.65% | 523,166 | – | – |
|
35
Adverum Biotechnologies
ADVM
$64.6M
| $15.1M | 0.64% | +1,069,244 | New | +$15.1M |
|
36
Puma Biotechnology
PBYI
$254M
| $14.9M | 0.63% | +2,816,294 | New | +$14.9M |
|
37
Tyra Biosciences
TYRA
$675M
| $13.6M | 0.58% | 832,220 -194,200 | -19% | -$3.18M |
|
38
Applied Therapeutics
APLT
$71M
| $13.3M | 0.56% | +1,952,857 | New | +$13.3M |
|
39
Allogene Therapeutics
ALLO
$251M
| $12.8M | 0.54% | +2,867,750 | New | +$12.8M |
|
40
Arvinas
ARVN
$568M
| $11.8M | 0.5% | 285,331 | – | – |
|
|
41
89bio
ETNB
$1.34B
| $11.6M | 0.49% | 1,000,000 -1,000,000 | -50% | -$11.6M |
|
42
Acadia Pharmaceuticals
ACAD
$4.38B
| $8.7M | 0.37% | 470,338 -260,579 | -36% | -$4.82M |
|
43
Cogent Biosciences
COGT
$1.69B
| $6.29M | 0.27% | 936,576 -1,058,691 | -53% | -$7.11M |
|
44
Intellia Therapeutics
NTLA
$1.22B
| $5.6M | 0.24% | 203,684 | – | – |
|
45
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$58.3M
| $5.52M | 0.23% | 500,333 | – | – |
|
46
AN2 Therapeutics
ANTX
$30.1M
| $4.51M | 0.19% | 1,388,889 | – | – |
|
47
Metagenomi
MGX
$65.3M
| $2.94M | 0.12% | +279,025 | New | +$2.94M |
|
|
GRTS
48
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $2.65M | 0.11% | 1,030,878 | – | – |
|
|
BLUE
49
DELISTED
bluebird bio
BLUE
| $2.19M | 0.09% | 1,709,907 | – | – |
|
50
Aclaris Therapeutics
ACRS
$209M
| $328K | 0.01% | 264,377 | – | – |
|